Release date: 2025-01-21 09:50:32 Article From: Lucius Laos Recommended: 84
Avatrombopag is a novel thrombopoietin receptor agonist, which has attracted much attention in clinical application.
Knowing the correct dosage of avatrombopag is critical to ensuring patient safety and efficacy.
The usual adult dose of avatrombopag is usually adjusted according to the patient's specific situation and the doctor's guidance. In general, the initial dose is set once daily for several days to achieve the desired platelet count level.
Dose adjustment is based on the patient's platelet response and clinical condition. If the platelet count is not as expected, your doctor may consider increasing the dose; Conversely, if the platelet count is too high or there are adverse reactions, the dose should be reduced as appropriate.
For special populations such as the elderly, patients with liver and kidney insufficiency, and pregnant women, the dose of avatrombopag needs to be individualized according to the specific situation of the patient. Doctors will take into account the patient's age, weight, liver and kidney function and other factors when prescribing.
In addition to dosage issues, it is equally important to understand the dosing precautions for avatrombopag.
Avatrombopag may interact with a variety of medications, such as certain antibiotics, antifungals, and immunosuppressants. During medication, patients should inform their doctor in detail about all medications they are taking to avoid potential drug interactions.
Avatrombopag may cause adverse effects such as headache, nausea, and vomiting. Patients should pay close attention to their own reactions during the medication and seek medical attention and inform their doctor immediately if they experience uncomfortable symptoms.
Patients should strictly follow the doctor's instructions and should not change the dose or stop the drug at will. Regular follow-up appointments allow your doctor to evaluate the response and adjust your treatment.
The dosage and precautions for avatrombopag are key to ensuring patient safety and efficacy. Patients should fully understand and follow the doctor's guidance and use drugs rationally in order to achieve the best treatment effect. Doctors should also pay close attention to the patient's medication situation and response, and adjust the treatment plan in time.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: